ClinicalTrials.gg
CompletedNCT04368585Updated Sep 4, 2020

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

A Phase 1 interventional study of Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) and 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy, adult, male or female, 18-55 years of age, inclusive, at the screening visit.
  • Continuous non-smoker
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.

Key Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected to have during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History of significant allergic disease requiring treatment
  • History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose.
  • History or presence of or idiosyncratic reaction to the study drugs or related compounds (especially fluoroquinolone-, carbapenem-, penicillin-, and cephalosporin-antibiotics sensitivity).
  • History of known genetic metabolism anomaly associated with carnitine deficiency (e.g., carnitine transporter defect, methylmalonic aciduria, propionic acidemia).
  • History of cholecystectomy.
  • Female subjects with a positive pregnancy test at the screening visit or first check-in or who are lactating.
  • Positive urine drug or alcohol results at the screening visit or first check-in.
  • Positive results at the screening visit for (HIV 1 and 2), surface antigen (HBsAg) or virus (HCV).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    TBPM-PI-HBr Alone (Period 1)

    Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

  • Experimental
    TBPM-PI-HBr and Antacid (Period 2)

    20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) · Drug: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)

  • Experimental
    TBPM-PI-HBr and Omeprazole (Period 3)

    40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) · Drug: Omeprazole

Interventions

  • Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

    Also known as: TBPM-PI-HBr, SPR994

  • Drug20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)

    Drug pages: Aluminum Hydroxide · Magnesium Hydroxide · Simethicone

    20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.

  • 40 mg (1 x 40 mg capsule) omeprazole administered QD

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  2. Area under the curve extrapolated to infinity (AUC0-∞).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  3. Percent of AUC0-inf extrapolated (AUC%extrap)

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  4. Maximum plasma concentration (Cmax).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  5. Time to the maximum plasma concentration (Tmax).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  6. Terminal elimination half-life (t½).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  7. Apparent total body clearance (CL/F)

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

  8. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).

    Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

Secondary outcomes

  1. Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.

    ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.

    Time frame: 12 to 14 days after the last dose of study drug

07

Study locations

1 site
  • Medical Facility
    Phoenix, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Aug 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 30, 2020
StartActual
Jul 1, 2020
Primary completionActual
Aug 8, 2020
CompletionActual
Aug 21, 2020
Last update
Sep 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04368585
Lead sponsor
Spero Therapeutics
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
Jul 1, 2020
Primary completion
Aug 8, 2020
Completion
Aug 21, 2020
Last update
Sep 4, 2020

Study contacts

David Melnick, M.D.
study director · Spero Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion